These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 29756366)

  • 1. Neuromelanin imaging and midbrain volumetry in progressive supranuclear palsy and Parkinson's disease.
    Taniguchi D; Hatano T; Kamagata K; Okuzumi A; Oji Y; Mori A; Hori M; Aoki S; Hattori N
    Mov Disord; 2018 Sep; 33(9):1488-1492. PubMed ID: 29756366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regional Selectivity of Neuromelanin Changes in the Substantia Nigra in Atypical Parkinsonism.
    Chougar L; Arsovic E; Gaurav R; Biondetti E; Faucher A; Valabrègue R; Pyatigorskaya N; Dupont G; Lejeune FX; Cormier F; Corvol JC; Vidailhet M; Degos B; Grabli D; Lehéricy S
    Mov Disord; 2022 Jun; 37(6):1245-1255. PubMed ID: 35347754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [
    Coakeley S; Cho SS; Koshimori Y; Rusjan P; Ghadery C; Kim J; Lang AE; Houle S; Strafella AP
    Brain Struct Funct; 2018 Mar; 223(2):589-595. PubMed ID: 28884232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRI evaluation of progressive supranuclear palsy: differentiation from Parkinson's disease and multiple system atrophy.
    Eraslan C; Acarer A; Guneyli S; Akyuz E; Aydin E; Colakoglu Z; Kitis O; Calli MC
    Neurol Res; 2019 Feb; 41(2):110-117. PubMed ID: 30373485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new MR imaging index for differentiation of progressive supranuclear palsy-parkinsonism from Parkinson's disease.
    Quattrone A; Morelli M; Nigro S; Quattrone A; Vescio B; Arabia G; Nicoletti G; Nisticò R; Salsone M; Novellino F; Barbagallo G; Le Piane E; Pugliese P; Bosco D; Vaccaro MG; Chiriaco C; Sabatini U; Vescio V; Stanà C; Rocca F; Gullà D; Caracciolo M
    Parkinsonism Relat Disord; 2018 Sep; 54():3-8. PubMed ID: 30068492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of neuromelanin-positive nigral volume in patients with MSA, PSP and CBD.
    Kashihara K; Shinya T; Higaki F
    Intern Med; 2011; 50(16):1683-7. PubMed ID: 21841326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Midbrain atrophy in patients with presymptomatic progressive supranuclear palsy-Richardson's syndrome.
    Ahn JH; Kim M; Kim JS; Youn J; Jang W; Oh E; Lee PH; Koh SB; Ahn TB; Cho JW
    Parkinsonism Relat Disord; 2019 Sep; 66():80-86. PubMed ID: 31307918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parkinson's disease-related increase of T2*-weighted hypointensity in substantia nigra pars compacta.
    Langley J; Huddleston DE; Sedlacik J; Boelmans K; Hu XP
    Mov Disord; 2017 Mar; 32(3):441-449. PubMed ID: 28004859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic resonance imaging evaluation of nigrosome 1 and neuromelanin can assist Parkinson's disease diagnosis, but requires an expert neuroradiologist.
    De Pietro Franco Zorzenon C; Almeida Antônio Bienes GH; Duarte Alves E; Tobaru Tibana LA; Carrete Júnior H; Ballalai Ferraz H
    Parkinsonism Relat Disord; 2021 Feb; 83():8-12. PubMed ID: 33418131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accuracy of MR markers for differentiating Progressive Supranuclear Palsy from Parkinson's disease.
    Zanigni S; Calandra-Buonaura G; Manners DN; Testa C; Gibertoni D; Evangelisti S; Sambati L; Guarino M; De Massis P; Gramegna LL; Bianchini C; Rucci P; Cortelli P; Lodi R; Tonon C
    Neuroimage Clin; 2016; 11():736-742. PubMed ID: 27330973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Midbrain area for differentiating Parkinson's disease from progressive supranuclear palsy.
    Ghourchian S; Mousavi A; Zamani B; Shahidi G; Rohani M
    Clin Neurol Neurosurg; 2019 Aug; 183():105383. PubMed ID: 31181432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Midbrain MRI assessments in progressive supranuclear palsy subtypes.
    Picillo M; Tepedino MF; Abate F; Erro R; Ponticorvo S; Tartaglione S; Volpe G; Frosini D; Cecchi P; Cosottini M; Ceravolo R; Esposito F; Pellecchia MT; Barone P; Manara R
    J Neurol Neurosurg Psychiatry; 2020 Jan; 91(1):98-103. PubMed ID: 31527182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of substantia nigra hyperintensity on 7 Tesla MRI of Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
    Kim JM; Jeong HJ; Bae YJ; Park SY; Kim E; Kang SY; Oh ES; Kim KJ; Jeon B; Kim SE; Cho ZH; Kim YB
    Parkinsonism Relat Disord; 2016 May; 26():47-54. PubMed ID: 26951846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnetic Resonance Parkinsonism Index and midbrain to pons ratio: Which index better distinguishes Progressive Supranuclear Palsy patients with a low degree of diagnostic certainty from patients with Parkinson Disease?
    Nigro S; Morelli M; Arabia G; Nisticò R; Novellino F; Salsone M; Rocca F; Quattrone A
    Parkinsonism Relat Disord; 2017 Aug; 41():31-36. PubMed ID: 28487107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson's disease.
    Biondetti E; Gaurav R; Yahia-Cherif L; Mangone G; Pyatigorskaya N; Valabrègue R; Ewenczyk C; Hutchison M; François C; Arnulf I; Corvol JC; Vidailhet M; Lehéricy S
    Brain; 2020 Sep; 143(9):2757-2770. PubMed ID: 32856056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-dimensional neuromelanin-sensitive magnetic resonance imaging of the substantia nigra in Parkinson's disease.
    Prasad S; Stezin A; Lenka A; George L; Saini J; Yadav R; Pal PK
    Eur J Neurol; 2018 Apr; 25(4):680-686. PubMed ID: 29341412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining quantitative susceptibility mapping to the morphometric index in differentiating between progressive supranuclear palsy and Parkinson's disease.
    Azuma M; Hirai T; Nakaura T; Kitajima M; Yamashita S; Hashimoto M; Yamada K; Uetani H; Yamashita Y; Wang Y
    J Neurol Sci; 2019 Nov; 406():116443. PubMed ID: 31634718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential Progression of Midbrain Atrophy in Parkinsonism: Longitudinal MRI Study.
    Hwang M; Yang H; Kim Y; Youn J; Park J; Huh YE; Kim HT; Cho JW
    Neurodegener Dis; 2017; 17(1):31-37. PubMed ID: 27614955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multimodal Magnetic Resonance Imaging Quantification of Brain Changes in Progressive Supranuclear Palsy.
    Pyatigorskaya N; Yahia-Cherif L; Gaurav R; Ewenczyk C; Gallea C; Valabregue R; Gargouri F; Magnin B; Degos B; Roze E; Bardinet E; Poupon C; Arnulf I; Vidailhet M; Lehericy S
    Mov Disord; 2020 Jan; 35(1):161-170. PubMed ID: 31710146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantifying changes in nigrosomes using quantitative susceptibility mapping and neuromelanin imaging for the diagnosis of early-stage Parkinson's disease.
    Takahashi H; Watanabe Y; Tanaka H; Mihara M; Mochizuki H; Liu T; Wang Y; Tomiyama N
    Br J Radiol; 2018 Jun; 91(1086):20180037. PubMed ID: 29498540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.